This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
JNJ Beats on Q2 Earnings, Cuts View: ETFs in Focus
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat. It outpaced revenue estimates as well but cut its full-year guidance on a strong dollar.
Pharma & Biotech ETFs at One-Month High: Here's Why
by Sanghamitra Saha
Pharma and biotech ETFs are in great shape and are trading at a one-month high level.
5 ETFs to Counter Imminent War-Induced Global Growth Slowdown
by Sanghamitra Saha
The pandemic-driven supply chain woes and the resultant red-hot inflation, the Russia-Ukraine war and the resultant hit to the commodity market as well as the central banks' policy tightening in the developed world may cause global growth slowdown in the coming days.
Pfizer ETFs to Rise on FDA's EUA for COVID-19 Oral Antiviral Pill
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the receipt of EUA for the antiviral COVID-19 pill.
Warm Up Your Portfolio With These ETFs This Winter
by Sanghamitra Saha
Uncertainties are playing a big role in the Wall Street due to record-high inflation, Fed policy tightening and Omicron strain of coronavirus. Still, some ETFs may warm up your winter portfolio.
Will Pfizer ETFs Soar on Positive COVID-19 Vaccine Updates?
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging updates in the coronavirus vaccine.
Will Pfizer ETFs Gain on Positive COVID-19 Booster Dose Data?
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in the coronavirus vaccine.
JNJ Posts Mixed Q3 Bag, Ups View: ETFs in Focus
by Sweta Killa
Johnson & Johnson (JNJ) continued its long streak of earnings beat but lagged the revenue estimates. The company lifted its full-year guidance.
ETFs to Play as Merck Shares Surge on COVID Treatment News
by Sanghamitra Saha
Merck & Co shares gained 8.4% on Oct 1, 2021 on news of success in its COVID treatment.
Take a Look at the Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.